Avidity Biosciences: Targeting A First Ever Approval In DM1 With Improving Data [Seeking Alpha]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: Seeking Alpha
The company's market cap valuation is approximately $1.5 billion. Its IPO raised $259 million in June 2020 at $18 per share. Avidity has attracted major pharma companies for collaborations and licensing agreements, potentially worth up to $2.2 billion and $405 million in milestone payouts, respectively. Lead candidate AOC-1001 - known as del desiran - has been subject to a partial clinical hold, which was partially lifted last year, allowing the Marin study to progress. Management wants to move del desiran into a pivotal study this year, in DM1, targeting approval in 2026. The market opportunity, efficacy and safety of the drug needs more clarification to derisk this potentially promising investment opportunity. Avidity Biosciences Overview San Diego-based Avidity Biosciences ( NASDAQ: RNA ) stock has gained 20% during the past five days, primarily due to the company's release of positive long-term data for its lead candidate, AOC 1001, otherwise known as delpacibart etedes
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- Artisan International Small-Mid Fund Q1 2024 Earnings Preview [Seeking Alpha]Seeking Alpha
- Strategies for Global Clinical Trials: Clinical Research Without Borders, Upcoming Webinar Hosted by XtalksPR Web
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- FYBR, BCRX and SABR are among after hour movers [Seeking Alpha]Seeking Alpha
- Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.MarketBeat
RNA
Earnings
- 2/28/24 - Miss
RNA
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- RNA's page on the SEC website